Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcceleRET-Lung: pralsetinib versus standard platinum-based therapy in first-line RET fusion-positive metastatic NSCLC
NL-OMON59332Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pralsetinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Aug 2020; status: completed.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59332.